7.40
+0.18
+(2.49%)
At close: April 17 at 4:00:01 PM EDT
7.30
-0.10
(-1.35%)
After hours: April 17 at 7:30:51 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
450,712
450,712
331,412
270,827
157,170
Cost of Revenue
12,485
12,485
4,661
6,594
7,264
Gross Profit
438,227
438,227
326,751
264,233
149,906
Operating Expense
440,770
440,770
430,460
412,668
327,626
Operating Income
-2,543
-2,543
-103,709
-148,435
-177,720
Net Non Operating Interest Income Expense
-83,770
-83,770
-92,462
-93,965
-59,232
Other Income Expense
-641
-641
-30,058
-1,983
55,143
Pretax Income
-86,954
-86,954
-226,229
-244,383
-181,809
Tax Provision
1,927
1,927
310
2,733
2,253
Net Income Common Stockholders
-88,881
-88,881
-226,539
-247,116
-184,062
Diluted NI Available to Com Stockholders
-88,881
-88,881
-226,539
-247,116
-184,062
Basic EPS
-0.61
-0.43
-1.18
-1.33
-1.03
Diluted EPS
-0.61
-0.43
-1.18
-1.33
-1.03
Basic Average Shares
205,226.25
206,696
192,198
185,908
179,117
Diluted Average Shares
205,226.25
206,696
192,198
185,908
179,117
Total Operating Income as Reported
-2,543
-2,543
-103,709
-148,435
-177,720
Total Expenses
453,255
453,255
435,121
419,262
334,890
Net Income from Continuing & Discontinued Operation
-88,881
-88,881
-226,539
-247,116
-184,062
Normalized Income
-88,374.61
-88,374.61
-202,793.18
-245,549.43
-224,316.39
Interest Income
14,746
14,746
15,777
5,127
62
Interest Expense
98,516
98,516
108,239
99,092
59,294
Net Interest Income
-83,770
-83,770
-92,462
-93,965
-59,232
EBIT
11,562
11,562
-117,990
-145,291
-122,515
EBITDA
12,808
12,808
-116,335
-143,854
-121,738
Reconciled Cost of Revenue
12,485
12,485
4,661
6,594
7,264
Reconciled Depreciation
1,246
1,246
1,655
1,437
777
Net Income from Continuing Operation Net Minority Interest
-88,881
-88,881
-226,539
-247,116
-184,062
Total Unusual Items Excluding Goodwill
-641
-641
-30,058
-1,983
55,143
Total Unusual Items
-641
-641
-30,058
-1,983
55,143
Normalized EBITDA
13,449
13,449
-86,277
-141,871
-176,881
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-134.61
-134.61
-6,312.18
-416.43
14,888.61
12/31/2021 - 3/4/1994
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DVAX Dynavax Technologies Corporation
10.31
-3.19%
AMRX Amneal Pharmaceuticals, Inc.
7.36
+2.51%
AQST Aquestive Therapeutics, Inc.
2.5100
+0.40%
IRWD Ironwood Pharmaceuticals, Inc.
0.7267
-3.11%
AVDL Avadel Pharmaceuticals plc
8.03
-1.47%
AKBA Akebia Therapeutics, Inc.
2.0600
+8.42%
KNSA Kiniksa Pharmaceuticals International, plc
20.21
-1.58%
ELAN Elanco Animal Health Incorporated
8.44
+4.20%
SCYX SCYNEXIS, Inc.
0.9043
-0.91%
ANIK Anika Therapeutics, Inc.
14.02
+4.08%